Fructose 1,6-bis phosphatase: getting the message across

Bioscience Reports
David J Timson

Abstract

Fructose 1,6-bisphosphatase (FBPase) is a key enzyme in gluconeogenesis. It is a potential drug target in the treatment of type II diabetes. The protein is also associated with a rare inherited metabolic disease and some cancer cells lack FBPase activity which promotes glycolysis facilitating the Warburg effect. Thus, there is interest in both inhibiting the enzyme (for diabetes treatment) and restoring its activity (in relevant cancers). The mammalian enzyme is tetrameric, competitively inhibited by Fructose 2,6-bisphosphate and negatively allosterically regulated by AMP. This allosteric regulation requires information transmission between the AMP binding site and the active site of the enzyme. A recent paper by Topaz et al. (Bioscience Reports (2019) 39, pii:BSR20180960) has added additional detail to our understanding of this information transmission process. Two residues in the AMP binding site (Lys112 and Tyr113) were shown to be involved in initiating the message between the two sites. This tyrosine residue has recently be shown to be important with protein's interaction with the antidiabetic drug metformin. A variant designed to increase metal ion affinity (M248D) resulted in a five-fold increase in enzymatic activity. I...Continue Reading

References

Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·H M KeW N Lipscomb
Jan 16, 1985·Biochemical and Biophysical Research Communications·W SchellenbergerE Hofmann
May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·E Van Schaftingen, H G Hers
May 10, 1995·Archives of Biochemistry and Biophysics·L F ShyurH J Fromm
May 11, 1999·Journal of Inherited Metabolic Disease·B HerzogK Eschrich
May 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Mark D ErionWilliam N Lipscomb
Nov 29, 2007·Journal of the American Chemical Society·Mark D ErionPaul D van Poelje
Jul 22, 2008·Nature Chemical Biology·Nina M Goodey, Stephen J Benkovic
Apr 8, 2009·Journal of Medicinal Chemistry·Qun DangMark D Erion
Apr 30, 2010·The Journal of Biological Chemistry·Ekaterina KuznetsovaAlexander F Yakunin
Apr 13, 2011·Handbook of Experimental Pharmacology·Paul D van PoeljeMark D Erion
Jul 22, 2014·Nature·Bo LiM Celeste Simon
Jan 21, 2015·Journal of Inherited Metabolic Disease·Elise LebigotAudrey Boutron
Apr 7, 2016·Acta Crystallographica. Section D, Structural Biology·Jakub BarciszewskiAndrzej Dzugaj
Jul 28, 2016·Applied Biochemistry and Biotechnology·Margaret McAuley, David J Timson
Sep 3, 2017·Current Opinion in Structural Biology·George P Lisi, J Patrick Loria
Oct 23, 2017·European Journal of Medicinal Chemistry·Ramandeep KaurManoj Kumar
Jan 27, 2018·Orphanet Journal of Rare Diseases·A PintoA MacDonald
Oct 27, 2018·Journal of Molecular Graphics & Modelling·Yunyuan HuangJian Wan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.